Letter
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial

https://doi.org/10.1016/j.jaad.2013.12.006Get rights and content

First page preview

First page preview
Click to open first page preview

References (5)

There are more references available in the full text version of this article.

Cited by (37)

  • Understanding the patient experience of living with notalgia paresthetica: A qualitative interview study

    2022, JAAD International
    Citation Excerpt :

    However, none of these treatments are approved for NP, and the only evidence of their clinical efficacy is from case reports. Additionally, guidelines for treating NP have not been published.3,5-8 To help select and develop effective treatments, the US Food and Drug Administration encourages considering the patient perspective.9

  • Alleviation of notalgia paresthetica with duloxetine after several lines offailed treatment: A case report

    2020, Case Reports in Women's Health
    Citation Excerpt :

    More recent trials of transcutaneous electrical nerve stimulation (TENS) showed mixed results. Importantly, NP is a benign condition, but can take months to years to resolve [4–7,2]. A recent review of treatments attempted to create an algorithmic approach to the use of the above-mentioned substances to provide an escalating treatment plan for NP [8].

  • Clinical presentation, management, and pathophysiology of neuropathic itch

    2018, The Lancet Neurology
    Citation Excerpt :

    A few case reports13,39,82,83have reported the efficacy of a high concentration (8%) capsaicin patch in patients with brachioradial pruritus, patients with notalgia paraesthetica, patients with HIV-associated peripheral NP, and in patients with diabetes-associated peripheral NP (appendix). Subcutaneous injections of botulinum toxin A, which blocks neuropeptide release from C-fibres, have shown efficacy in some patients with NI.84,85 Oral medications are the main treatment option for patients with widespread NI and for those with focal itch refractory to topical treatments (appendix).17,21,26,86

  • Diagnosis and Management of Neuropathic Itch

    2018, Dermatologic Clinics
    Citation Excerpt :

    Botulinum toxin may decrease pruritus through the reduction of cholinergic transmission or release of substance P along itch pathways. The authors have had some success with this treatment; however, such benefits were not substantiated in a 20-patient double-blinded controlled study.84 It is also speculated that botulinum toxin A may be useful in other forms of neuropathic itch, such as brachioradial pruritus.85

  • Laser treatment of medical skin disease in women

    2017, International Journal of Women's Dermatology
View all citing articles on Scopus

Funding sources: This study was funded by an investigator grant from Merz Pharmaceuticals LLC.

Disclosure: Catherine Maari and Robert Bissonnette have both been investigators for Allergan.

View full text